Seattle Genetics announces publication of results from two tucatinib phase 1b trials
Seattle Genetics announced that results of a phase 1b clinical trial of tucatinib in combination with standard of care agents for treatment of patients with advanced HER2-positive metastatic breast cancer were published in the journal The Lancet Oncology. July 11, 2018